The advances of aging research to be presented at the Basel Life Congress

Monday, August 6, 2018, Rockville, MD – Insilico Medicine, a Rockville-based company specializing in the application of next-generation artificial intelligence for drug discovery, biomarker development and aging research, announces the presentation of Morten Scheibye-Knudsen, PhD, MD, University of Copenhagen, at 5th Annual Aging and Drug Discovery Forum at Basel Life Congress, during the Basel Life Congress, September 12-13, 2018, Basel, Switzerland.

Morten Scheibye-Knudsen will give a talk titled "Phenotypical Landscape of Aging" covering the latest advances in the aging and longevity science at the Aging and Drug Discovery Forum.

"Aging is arguably the most complex of phenotypes, however the nature of the events leading to age-associated pathologies is largely unknown. In my talk, I will highlight our recent endeavors in understanding what drives specific aging phenotypes such as diabetes, neurodegeneration, and cancer. Importantly, this knowledge also allows us to develop interventions targeting aging and age-associated diseases. Our goal: to allow everyone to live healthier and longer lives." said Dr. Morten Scheibye-Knudsen, University of Copenhagen.

Aging and Drug Discovery Forum will gather a phenomenal group of thought-leaders to uncover the latest progress in aging and longevity at the molecular, cellular and organismal level. A panel of world leading experts will give their cutting edge reports on the latest progress in the quest to extend our healthy lifespan. There will will be talks from both academic and top investors on where and how commercialization of aging and longevity research will likely occur.

###

Insilico Medicine is regularly publishing research papers in peer-reviewed journals. The company was first to apply the generative adversarial networks (GANs) to generation of the new molecular structures with the specified parameters and published a seminal peer-reviewed paper submitted in June 2016. The concept was further extended and augmented with advanced memory and reinforcement learning. The paper published in Molecular Pharmaceutics in 2016 demonstrated the first proof of concept of the application of deep neural networks for predicting the therapeutic class of the molecule using the transcriptional response data, received the American Chemical Society Editors' Choice Award. One of the latest paper published in the Journals of Gerontology demonstrated the application of the deep neural networks to assessing the biological age of the patients.

For further information, images or interviews, please contact:

Contact: Qingsong Zhu, PhD
[email protected]

Website: insilico.com

Official Forum Website: https://www.basellife.org/basel-life-2018/basel-life/innovation-forums/scientific-programme/artificial-intelligence-and-blockchain-in-healthcare.html

About Insilico Medicine, Inc

Insilico Medicine is an artificial intelligence company headquartered at in Rockville, with R&D and management resources in Belgium, Russia, UK, Taiwan and Korea sourced through hackathons and competitions. The company and its scientists is dedicated to extending human productive longevity and transforming every step of the drug discovery and drug development process through excellence in biomarker discovery, drug development, digital medicine and aging research. Insilico pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets. In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with LifeExtension.com the company launched a range of nutraceutical products compounded using the advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI. In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. In 2018 it received the Frost & Sullivan 2018 North American Artificial Intelligence for Aging Research and Drug Development Award accompanied with the industry brief. Brief company video: https://www.youtube.com/watch?v=l62jlwgL3v8. http://www.insilico.com

Media Contact

Qingsong Zhu
[email protected]
410-733-5097
@InSilicoMeds

http://www.insilicomedicine.com

Comments